PROPANC BIOPHARMA, INC.: 10-Q filed 2013-02-20

Name: PROPANC BIOPHARMA, INC.: 10-Q filed 2013-02-20
Creator: PROPANC BIOPHARMA, INC.

What PROPANC BIOPHARMA, INC. reported in its quarterly report filed 2013-02-20 (fiscal Q2 2013): 29 published measures, 86 facts as tagged in accession 0001354488-13-000756.

This filing

Form: 10-Q (quarterly report)
Filed: 2013-02-20
Fiscal period: fiscal Q2 2013
Accession: 0001354488-13-000756 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PROPANC BIOPHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2012-12-31	12,300	USD
At 2012-06-30	46,268	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2012-12-31	-643,221	USD
At 2012-06-30	-537,919	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2012-12-31	494	USD
At 2012-06-30	179	USD
At 2011-12-31	39,728	USD
At 2011-06-30	132	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2012-10-01 to 2012-12-31	-387,753	USD	92
2012-07-01 to 2012-12-31	-880,318	USD	184
2007-10-15 to 2012-12-31	-16,161,032	USD	1905
2011-10-01 to 2011-12-31	-2,712,127	USD	92
2011-07-01 to 2011-12-31	-5,782,033	USD	184

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2012-07-01 to 2012-12-31	-77,898	USD	184
2007-10-15 to 2012-12-31	-2,600,687	USD	1905
2011-07-01 to 2011-12-31	-40,157	USD	184

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2007-10-15 to 2012-12-31	14,786	USD	1905

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2012-07-01 to 2012-12-31	74,025	USD	184
2007-10-15 to 2012-12-31	2,682,407	USD	1905
2011-07-01 to 2011-12-31	80,330	USD	184

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2007-10-15 to 2012-12-31	-40,512	USD	1905

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2012-10-01 to 2012-12-31	-61,120	USD	92
2012-07-01 to 2012-12-31	-61,120	USD	184
2007-10-15 to 2012-12-31	-319,629	USD	1905
2011-10-01 to 2011-12-31	-170,491	USD	92
2011-07-01 to 2011-12-31	-173,894	USD	184

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2012-12-31	4,006	USD
At 2012-06-30	4,617	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2007-10-15 to 2012-12-31	299,737	USD	1905

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2012-10-01 to 2012-12-31	-446,897	USD	92
2012-07-01 to 2012-12-31	-942,760	USD	184
2007-10-15 to 2012-12-31	-16,297,740	USD	1905
2011-10-01 to 2011-12-31	-2,879,177	USD	92
2011-07-01 to 2011-12-31	-5,951,989	USD	184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2012-12-31	8,294	USD
At 2012-06-30	41,651	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2012-10-01 to 2012-12-31	1,178	USD	92
2012-07-01 to 2012-12-31	2,623	USD	184
2007-10-15 to 2012-12-31	176,786	USD	1905
2011-10-01 to 2011-12-31	614	USD	92
2011-07-01 to 2011-12-31	797	USD	184

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2012-12-31	655,521	USD
At 2012-06-30	584,187	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2012-12-31	198,407	USD
At 2012-06-30	192,473	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2012-10-01 to 2012-12-31	446,897	USD	92
2012-07-01 to 2012-12-31	942,760	USD	184
2007-10-15 to 2012-12-31	16,328,714	USD	1905
2011-10-01 to 2011-12-31	2,879,177	USD	92
2011-07-01 to 2011-12-31	5,951,989	USD	184

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2012-10-01 to 2012-12-31	1,744	USD	92
2012-07-01 to 2012-12-31	1,744	USD	184
2007-10-15 to 2012-12-31	645,067	USD	1905
2011-07-01 to 2011-12-31	5,278	USD	184

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2012-12-31	72,820,339	shares
At 2012-06-30	72,705,569	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2012-12-31	15,814,011	USD
At 2012-06-30	15,029,326	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2012-12-31	-369,030	USD
At 2012-06-30	-358,917	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2012-12-31	5,417	USD
At 2012-06-30	38,520	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2012-10-01 to 2012-12-31	-387,946	USD	92
2012-07-01 to 2012-12-31	-890,431	USD	184
2007-10-15 to 2012-12-31	-16,530,062	USD	1905
2011-10-01 to 2011-12-31	-2,459,671	USD	92
2011-07-01 to 2011-12-31	-6,116,603	USD	184

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2012-10-01 to 2012-12-31	441,817	USD	92
2012-07-01 to 2012-12-31	934,419	USD	184
2007-10-15 to 2012-12-31	15,620,470	USD	1905
2011-10-01 to 2011-12-31	2,875,967	USD	92
2011-07-01 to 2011-12-31	5,940,245	USD	184

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2012-07-01 to 2012-12-31	708	USD	184
2007-10-15 to 2012-12-31	10,857	USD	1905
2011-07-01 to 2011-12-31	973	USD	184

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2012-10-01 to 2012-12-31	-1,976	USD	92
2012-07-01 to 2012-12-31	1,322	USD	184
2007-10-15 to 2012-12-31	-182,922	USD	1905
2011-10-01 to 2011-12-31	-3,441	USD	92
2011-07-01 to 2011-12-31	-3,938	USD	184

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2007-10-15 to 2012-12-31	1,479,675	USD	1905
2011-07-01 to 2011-12-31	10,321	USD	184

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2007-10-15 to 2012-12-31	-664	USD	1905

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2012-07-01 to 2012-12-31	26,934	USD	184
2007-10-15 to 2012-12-31	208,357	USD	1905
2011-07-01 to 2011-12-31	49,951	USD	184

Inspect the source

Entity: PROPANC BIOPHARMA, INC. / CIK 0001517681
Captured: 2026-09-20T09:14:07.933Z
SEC response SHA-256: 4f6eac6bf72e7f988a9a94ea85589b445974414449c4b417540ed20477181487

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001517681.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))